APREA THERAPEUTICS INC
APRENASDAQ🏆 #3754 by market capUS Equity
$574.60▼ $25.68 (−4.47%)
Simulated price1h—
24h▼ 4.5%
7d—
14d—
30d—
1y—
🏦Market Cap
$8M
Small Cap
📈Revenue Growth (YoY)
-90.4%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
28.2x
Expensive
Otter Score
46
Weak
No chart data available for APRE.
Trading Snapshot
- Day Range
- $567.41 – $582.76
- 52-Week Range
- $0.55 – $1.79
- Volume
- $2.24B
- Avg Volume
- $1.73B
- Shares Outstanding
- 12.4M
- Next Earnings
- Sep 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $290,200
- Last Q Revenue
- $65,785
- P/E Ratio
- —
- P/S Ratio
- 28.2x
- EPS (TTM)
- $-1.54
- Dividend Yield
- —
Why Investors Own APRE
- ✓High-growth profile — revenue up -7.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 32% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$290,200▼ −11.1% YoY
Gross Margin (TTM)
31.5%▲ +3.3% YoY
Operating Income (TTM)
$60,652▼ −11.1% YoY
Free Cash Flow (TTM)
$75,742▼ −11.1% YoY
About APREA THERAPEUTICS INC
A company profile for APREA THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$591.18
▲ +2.9% Upside
High Target$675.47
Low Target$465.77
Based on 21 analysts
Latest News & Updates
🚀
CNBC·2h ago
APREA THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift APRE price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
APREA THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.